<DOC>
	<DOCNO>NCT00056433</DOCNO>
	<brief_summary>Patients sickle cell disease abnormal hemoglobin ( protein red blood cell carry oxygen body ) . This abnormality cause red blood cell take sickle shape , produce disease symptom . Fetal hemoglobin , type hemoglobin present fetus baby , prevent red cell sickling . The drug hydroxyurea increase fetal hemoglobin production patient sickle cell disease making molecule call nitric oxide . The drug L-arginine Sildenafil ( Viagra ) increase amount effect nitric oxide . This study evaluate : - The safety give L-arginine Sildenafil together hydroxyurea patient sickle cell disease ; - The effectiveness L-arginine plus hydroxyurea Sildenafil plus hydroxyurea increase fetal hemoglobin patient sickle cell disease ; - The effectiveness L-arginine plus hydroxyurea Sildenafil hydroxyurea lower blood pressure lungs patient sickle cell disease . ( Pulmonary blood pressure elevate one-third patient sickle cell disease , condition increase risk die disease . ) Patients hemoglobin S-only , S-beta-thalassemia , sickle cell disease genotype may eligible study . Before start treatment , patient complete medical history physical examination . All patient take hydroxyurea day every day mouth least 2 month . They admit NIH Clinical Center take first dose hydroxyurea , blood drawn catheter ( plastic tube place vein ) every hour 6 hour test determine nitric oxide level . After discharge , return clinic every 2 week check treatment side effect blood test monitor hemoglobin fetal hemoglobin level . After fetal hemoglobin level stable 2 month , patient admit Clinical Center first dose L-arginine ( men ) Sildenafil ( woman ) . Again , blood sample collect catheter hour 6 hour . If complication , patient discharge continue take hydroxyurea day L-arginine Sildenafil three time day least 3 month fetal hemoglobin level stable least 2 month . Patients return clinic blood test every week 2 week every 2 week monitor hemoglobin fetal hemoglobin level check treatment side effect . Patients eye examination treatment . Some patient sickle cell disease develop abnormality blood vessel eye . Also , Sildenafil cause temporary change color vision . Rarely , serious eye problem occur , bleed eye blood vessel damage retina layer tissue line back eye . Patients also echocardiogram ( ultrasound heart ) begin treatment , hydroxyurea treatment , 1 3 month combine treatment hydroxyurea L-arginine Sildenafil help measure blood pressure lung . Patients develop complication L-arginine Sildenafil may continue study hydroxyurea alone . Patients whose fetal hemoglobin level increase combination therapy hydroxyurea L-arginine Sildenafil may continue take .</brief_summary>
	<brief_title>Evaluation Hydroxyurea Plus L-arginine Sildenafil Treat Sickle Cell Anemia</brief_title>
	<detailed_description>Hydroxyurea cell-cycle specific agent block DNA synthesis inhibit ribonucleotide reductase , enzyme convert ribonucleotides deoxyribonucleotides . Hydroxyurea show induce production fetal hemoglobin ( HbF ) , initially non-human primate , patient sickle cell anemia . The majority patient sickle cell disease respond drug two-fold increase HbF level ; patient percent HbF exceed 10 15 percent . It estimate level 20 percent require substantially reduce sickling propensity red cell modulate disease severity . We recently find hydroxyurea therapy associate intravascular intraerythrocytic generation nitric oxide ( NO ) , NO account HbF induction via guanylyl cyclase/cGMP dependent pathway . In fact , NO donor S-nitroso-cysteine NONOates similarly induce HbF expression human erythropoietin treat human CD 34+ stem cell . Possible synergy NO donor therapy classic cytostatic differentiating medication explore . We propose treat several patient chronically hydroxyurea determine hematological change Iongitudinally . Once maximal Hb-F raise effect hydroxyurea establish , oral L-arginine ( substrate NO synthase ) sildenafil ( Viagra , phosphodiesterase inhibitor potentates cGMP dependent signal ) add determine ability agent enhance HbF synthesis , especially hydroxyurea non-responders partial-responders . Additionally , find 33 % patient sickle cell disease also secondary pulmonary hypertension , measure echocardiogram . A secondary endpoint study evaluate chronic hydroxyurea therapy addition L-arginine sildenafil improve pulmonary hypertension subgroup .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Patients must document hemoglobin Sonly , Sbetathalassemia , sickle cell disease genotype . Only patient hemoglobin Sonly consider primary analysis . 2 . Patients must relatively well preserved renal hepatic function ( creatinine le 1.6 mg/dl normal liver function test le 5 X normal ALT ) . 3 . Evidence severe sickle cell anemia include one following : recurrent pain crisis ( great equal 2 ER visit per year ) , recurrent acute chest syndrome ( lung problem like pneumonia ) , hospitalization , leg ulceration , priapism , aseptic necrosis hip , and/or pulmonary hypertension . 4 . Patients must able provide inform consent . EXCLUSION CRITERIA : 1 . Patients hemoglobin S A ( trait ) hemoglobin Aonly ( nonsickle cell ) . 2 . Patients must chronic transfusion program , define regular transfusion every 28 week . 3 . Patients must pregnant breast feeding . 4 . Patients chronic nitrate , nitroglycerin .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 7, 2015</verification_date>
	<keyword>Fetal Hemoglobin Induction</keyword>
	<keyword>L-Arginine</keyword>
	<keyword>Nitric Oxide Therapy</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Sildenafil ( Viagra )</keyword>
	<keyword>Sickle Cell Anemia</keyword>
</DOC>